MedDataX Logo

Study to Develop a Breath Analyser to Detect Chronic Kidney Disease

NCT ID: NCT03303222

Last Updated: 2020-11-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-02-10

Study Completion Date

2023-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Measure trimethylamine oxide in the breath.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Organic compounds such as trimethylamine oxide (TMAO) accumulate in the blood of patients with kidney disease, and volatile compounds such as TMAO can be detected in the breath.

The investigators wish to develop a breath analyser to measure volatile compounds, such as TMAO in the breath in patients with kidney disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kidney Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients on dialysis

patients with kidney disease treated by dialysis

breath

Intervention Type DIAGNOSTIC_TEST

measurement of volatile compounds, such as TMAO in exhaled breath and blood

patients with chronic kidney disease

patients with chronic kidney disease not treated by dialysis

breath

Intervention Type DIAGNOSTIC_TEST

measurement of volatile compounds, such as TMAO in exhaled breath and blood

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

breath

measurement of volatile compounds, such as TMAO in exhaled breath and blood

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

blood sample

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with kidney disease under the care of Royal Free Hospital

Exclusion Criteria

* patients unable to provide informed consent
* patients unable to exhale into breath analyser
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University College, London

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

andrew davenport, md

Role: PRINCIPAL_INVESTIGATOR

UCL, London

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

andrew davenport, md

Role: CONTACT

[email protected]
442077940500

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRAS 228416

Identifier Type: -

Identifier Source: org_study_id